We use necessary cookies to make our website work. We'd also like to use optional cookies to understand how you use it, and to help us improve it.

For more information, please read our cookie policy.

UK Civil Aviation Regulations

These are published by the CAA on our UK Regulations pages. EU Regulations and EASA Access Guides published by EASA no longer apply in the UK. Our website and publications are being reviewed to update all references. Any references to EU law and EASA Access guides should be disregarded and where applicable the equivalent UK versions referred to instead.



Oxybutynin MR (Lyrinel XL)

It is not acceptable for short-term use prior to bladder surgery. Only the sustained-release formulation is permitted.

Tolterodine MR (Detrusitol XL)

Solifenacin (Vesicare)

Darifenacin (Emselex)

Trospium IR and MR (Regurin)

Side-effects to enquire about are mainly anti-cholinergic such as dry mouth, blurred vision and drowsiness. If these do not occur in the first few months they are extremely unlikely to occur later.

Class 1

Unfit for a minimum of four weeks or until a stable dose is achieved with adequate symptom control.
OML for at least four months.

If the dose of drug remains stable with satisfactory symptom control and no reported side-effects, then unrestricted certification can be considered at four months. Any change in dosage should entail a grounding period of four weeks followed by reassessment. Pilots should be advised to keep themselves hydrated before and during flights.

Class 2

Unfit for a minimum of four weeks or until a stable dose to achieve with adequate symptom control. If the dose of drug remains stable with satisfactory symptom control and no reported side-effects, then unrestricted certification can be considered at four weeks. Any change in dosage should entail a grounding period of four weeks, followed by reassessment.